Corriente Advisors’s Epizyme, Inc EPZM Stock Holding History

Corriente Advisors’s Portfolio EPZM Stock Details EPZM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-230,000	Closed	-$3.57M	–	20
2020 Q1	$3.57M	Buy	+230,000	New	+$4.94M	3.85%	7

Other funds holding EPZM

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

RP Management New York $139M AUM 37.98% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Corriente Advisors's EPZM Position: Q2 2020 in Review

Corriente Advisors sold out of Epizyme, Inc (EPZM) in Q2 2020, closing a stake of 230,000 shares — an estimated $3.57M sold.

Corriente Advisors first reported a position in EPZM in Q1 2020 and held it in 1 quarter. The position peaked at $3.57M in Q1 2020. 160 funds tracked by Wall St. Rank hold EPZM as of Q2 2020.

Corriente Advisors reported no remaining Epizyme, Inc position as of Q2 2020 after selling out during the quarter.
Corriente Advisors sold 230,000 Epizyme, Inc shares in Q2 2020, an estimated $3.57M.
Corriente Advisors first reported a position in Epizyme, Inc in Q1 2020 and held it in 1 quarter.
Corriente Advisors's Epizyme, Inc position peaked at $3.57M in Q1 2020.
160 funds tracked by Wall St. Rank held Epizyme, Inc as of Q2 2020.

Based on Corriente Advisors's 13F filing for Q2 2020, filed 14 Aug 2020.